Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of AZD0171 with Durvalumab and Chemotherapy in Metastatic Solid Tumours
2021-002040-78Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of AZD0171 in pancreatic adenocarcinoma (PDAC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Pharmacokinetics of AZD0171. Started Aug 2021; status: completed.
02
Drugs
AZD0171
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2021-002040-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002040-78.